Phase II open ‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

ConclusionsAfatinib showed similar ORR and PFS in patients with lung cancer harboring EGFRm in their ctDNA regardless of tumor EGFRm results.Key pointsSignificant findings of the studyAfatinib showed favorable ORR and PFS regardless of the tumorEGFR mutation status results, similar to the findings of previous trials assessing afatinib as first ‐line treatment ofEGFR‐mutated non‐small cell lung cancer based on tumor genotyping.What this study addsOur findings emphasize that the survival benefit of afatinib treatment can be achieved not only by appropriate dose reduction with frequent and detailed monitoring of toxicities, but also by using noninvasive (ctDNA) assays in a real ‐world setting.

Source: Thoracic Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Cheol ‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim Tags: ORIGINAL ARTICLE Source Type: research